The effectiveness of the drug Vessel Due F in patients with diabetes with nonproliferative and preproliferative diabetic retinopathy
The results of the study of clinical significance of glycosaminoglycans (sulodeksid - Vessel Due F) use in combination with laser coagulation of the retina for the prevention and treatment of primary and expressed stages of diabetic retinopathy (DR) in 191 patients with diabetes mellitus (DM) are presented. According to the analysis of the dynamics of ocular fundus state in patients with diabetes for 2 years after treatment, sulodeksid administration reduces microvascular abnormalities in patients with early changes in the ocular fundus. The laser coagulation in combination with the sulodeksid administration provides a persistent positive effect on the course of the disease in diabetic patients with nonproliferative and preproliferative DR. Refresher several courses of laser coagulation in combination with use of Vessel Due F are necessary to achieving the process stabilization in diabetic patients with marked changes in the ocular fundus.